Latest Conference Articles

April 28th 2016, 8:00am

Oncology Nursing Society Congress

Lots of people take their work home with them, but Lynne Malestic, RN, has given the idea new meaning.

April 28th 2016, 8:00am

Oncology Nursing Society Congress

Carmela Hoefling, RN, MSN, APN-C, AOCNP, advanced practice nurse, Gastrointestinal/Hepatobiliary Oncology Program, Rutgers Cancer Institute of New Jersey, discusses the effects that malnourishment can have on surgery.

April 28th 2016, 8:00am

Oncology Nursing Society Congress

Joel Stettler, BSN, RN, OCN, Moffitt Cancer Center, discusses procedures implemented at his institution for patients who are at risk for falls. 

April 28th 2016, 8:00am

Oncology Nursing Society Congress

Developing a skin rash as a result of EGFR-inhibitor targeted therapy often signals that the drug is working, but for patients who experience these serious dermatologic adverse events, it may become so intolerable that they will scale back or even discontinue anticancer medications that could prolong their survival.

April 28th 2016, 8:00am

Oncology Nursing Society Congress

With the growing use of oral therapies in cancer care, it is crucial that oncology nurses are using a systematic approach to assess and improve adherence, according to Whitney Perry, APRN, AOCNP.

April 28th 2016, 7:50am

Oncology Nursing Society Congress

The possibility that hospitalized cancer patients will fall is an ongoing concern among the medical professionals who care for them.

April 28th 2016, 7:42am

Oncology Nursing Society Congress

Darcy Burbage, RN, MSN, AOCN, CBCN, Helen F. Graham Cancer Center & Research Institute, discusses the role nurses play in treating patients with chemotherapy-induced peripheral neuropathy (CIPN).

April 26th 2016, 12:25pm

Community Oncology Conference

David Eagle, MD, past president of the Community Oncology Alliance (COA) and partner in Lake Norman Oncology, Mooresville, North Carolina, discuss controlling costs of cancer treatment.

April 26th 2016, 9:43am

School of Gastrointestinal Oncology

Jeff Geschwind, MD, professor and chairman, Radiology and Biomedical Imaging, Yale Cancer Center, discusses locoregional treatment options for patients with hepatocellular carcinoma (HCC).

April 26th 2016, 9:13am

School of Gastrointestinal Oncology

A number of novel therapies are currently being explored as second-line treatments for patients with advanced hepatocellular carcinoma, including a host of targeted therapies and various immune checkpoint inhibitors.

April 26th 2016, 9:04am

School of Gastrointestinal Oncology

Immunotherapy approaches are showing early signs of activity against a range of gastrointestinal cancers, defying the skeptical view that these tumors would not respond to the emerging agents succeeding in other malignancies.

April 26th 2016, 7:46am

School of Gastrointestinal Oncology

Douglas B. Evans, MD, FACS, Chair, Professor, Donald C. Ausman Family Foundation Professor of Surgery, Medical College of Wisconsin, discusses how to appropriately sequence therapies for pancreatic cancer.

April 26th 2016, 6:53am

School of Gastrointestinal Oncology

Michael Choti, MD, explains the impact of advancements in the treatment of patients with liver cancer and how building on them will require all oncology professionals to work as a team.

April 23rd 2016, 11:43am

School of Gastrointestinal Oncology

Cancer care is shifting from a consumption to a value-based model, and precision oncology should play a vital role in that process by helping to deliver more effective therapies with more manageable pricing profiles.

April 23rd 2016, 11:06am

School of Gastrointestinal Oncology

Given the numerous available treatment options, the most important issue in frontline colorectal cancer care is clarifying the goals of therapy.

April 23rd 2016, 9:28am

School of Gastrointestinal Oncology

Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses about 2 agents, regorafenib and TAS-102, for the treatment of patients with treat colorectal cancer.

April 23rd 2016, 8:05am

School of Gastrointestinal Oncology

John L. Marshall, MD, discusses how the management of patients with gastrointestinal cancers requires a multidisciplinary approach.

April 23rd 2016, 6:11am

School of Gastrointestinal Oncology

Dr. Christopher Heery, medical oncologist, National Cancer Institute, discusses the progress that has been made in the treatment of patients with neuroendocrine tumors.

April 20th 2016, 4:30pm

AACR Annual Meeting

More than one-third of patients with previously untreated renal cell carcinoma responded to the combination of high-dose interleukin-2 and an investigational histone deacetylase inhibitor entinostat.

April 20th 2016, 8:47am

AACR Annual Meeting

Robert Ferris, MD, PhD, vice chair for Clinical Operations, associate director for Translational Research, and coleader of the Cancer Immunology Program at the University of Pittsburgh Cancer Institute, discusses the CheckMate-141 trial, which found that treatment with single-agent nivolumab (Opdivo) reduced the risk of death by 30% and doubled 1-year overall survival (OS) rates compared investigator's choice of therapy for patients with recurrent or metastatic head and neck squamous cell carcinoma (SCCHN).